New CMV vaccine candidate passes first safety check in healthy volunteers
NCT ID NCT06145178
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 28 times
Summary
This early-stage trial tested a new vaccine called SPYVLP01 designed to prevent cytomegalovirus (CMV) infection. Researchers gave the vaccine to 120 healthy adults aged 18-50 to see if it is safe and triggers an immune response. The study compared two different doses, with and without adjuvants (boosters), to find the best approach for future testing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Medicines Evaluation Unit
Manchester, United Kingdom
-
Velocity Bristol
Bristol, United Kingdom
Conditions
Explore the condition pages connected to this study.